本頁只刊出中文翻譯與中文說明；英文原文請見下方原文連結。
原文連結
論文資訊
- 類型：已發表論文
- 日期：2025-10-15
摘要
Annually, influenza 流行病學cs lead to hundreds of thousands of deaths worldwide many more hospitalizations. The antivirals baloxavir and oseltamivir improve outcomes and limit 病毒 spread, but their widespread use may accelerate the 湧現 of drug-resistant influenza variants, particularly in young children. Using a data-driven model, we assess various age-stratified antiviral treatment strategies, in terms of reducing both illness and the risk of resistance. In a typical influenza season in the United States, administering baloxavir to 20% of symptomatic individuals >5 years old would be expected to reduce the median disability-adjusted life-years (DALYs) lost by 32.3%, but with a 26.4% risk of resistance transmitting widely. If those patients instead received oseltamivir, DALYs lost would decreas
※ 此為已發表論文，全文需透過期刊付費取得